Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy

DISEASE CHARACTERISTICS: Histologically proven stage IC, II, III, or IV ovarian epithelial carcinoma or primary peritoneal serous carcinoma Prior complete response to 1 platinum-based chemotherapy regimen consisting of at least 5 courses Absence of disease on physical and radiological exam (CT scan/MRI) CA 125 normal No visible evidence of malignant disease on second-look laparoscopy No disease relapse even if complete response to a second course of chemotherapy Prior bilateral oophorectomy with or without salpingectomy, omentectomy, and total or partial abdominal hysterectomy required No known metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10.0 g/dL Hepatic: SGOT/SGPT no greater than 2 times upper limit of normal Renal: Creatinine no greater than 2.0 mg/dL Other: No other malignancy except basal cell skin cancer No serious physical or psychiatric disease that would preclude study entry No significant loculation that would preclude good distribution of study medication Human antimouse antibody negative PRIOR CONCURRENT THERAPY: Biologic therapy: No prior murine antibody Chemotherapy: See Disease Characteristics No more than 4-8 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics Other: No concurrent participation in other trials involving adjuvant cancer treatment No other concurrent experimental therapies